Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization

H. V. Naina, R. K. Pruthi, D. J. Inwards, D. Dingli, M. R. Litzow, S. M. Ansell, H. J. William, A. Dispenzieri, F. K. Buadi, M. A. Elliott, D. A. Gastineau, M. A. Gertz, S. R. Hayman, P. B. Johnston, M. Q. Lacy, I. N. Micallef, L. F. Porrata, S. Kumar

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The use of erythropoietic agents has been associated with an increased risk of venous thromboembolic events (VTEs), especially in patients with underlying malignancies. However, it is not known whether there is an increased risk of VTE associated with granulocyte growth factors. We reviewed 621 patients undergoing PBSC mobilization using granulocyte growth factors, alone or in combination with CY. Patients with a diagnosis of AL amyloidosis (AL: 114; 18%), multiple myeloma (MM: 278; 44%) Hodgkin lymphoma (HL: 20; 3%) or non-Hodgkin lymphoma (NHL: 209; 33%) were included. Symptomatic VTE occurred in six (0.97%) patients: two AL, two MM and two NHL. Of the six patients, two had pulmonary embolism, one developed deep vein thrombosis and three developed symptomatic catheter related thrombosis. Two patients with AL had heparin-induced thrombocytopenia and thrombosis. We found a low incidence of VTE among patients undergoing PBSC mobilization.

Original languageEnglish (US)
Pages (from-to)291-293
Number of pages3
JournalBone Marrow Transplantation
Volume46
Issue number2
DOIs
StatePublished - Feb 2011

Keywords

  • G-CSF
  • stem cell mobilization
  • venous thrombosis

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization'. Together they form a unique fingerprint.

Cite this